Therapy-related acute myelomonocytic leukemia following successful treatment for acute promyelocytic leukemia

E. Todisco, A. M. Testi, G. Avvisati, M. L. Moleti, M. Cedrone, G. Cimino, F. Mancini, S. Amadori, F. Mandelli

Research output: Contribution to journalArticlepeer-review

Abstract

We report a case of therapy-related acute myeloid leukemia (t-AML), M4 FAB subtype, with t(10;11)(p14;q21) chromosome abnormality developed in a patient treated for acute promyelocytic leukemia (APL) after 4 years of continuous complete remission (CCR). Two distinct forms of t-AML have been described: the classical type and the second type. Our case has many characteristics in common with the second type of t-AML such as: exposure to topoisomerase II active agents (idarubicin (IDA), mitoxantrone (MITOX), etoposide (VP16)), M4 FAB subtype, a latency period of 39 months and absence of a preleukemic phase. However, it differs in the chromosome 11 breakpoint (band q21 instead of q23) and absence of ALL-1 (Hrx, MLL, Htrx) gene involvement. This can represent the second observation of t-AML occurring after treatment for APL.

Original languageEnglish
Pages (from-to)1583-1585
Number of pages3
JournalLeukemia
Volume9
Issue number9
Publication statusPublished - 1995

Keywords

  • Acute promyelocytic leukemia
  • DNA topoisomerase II targeting agent
  • Therapy-related leukemia

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Fingerprint

Dive into the research topics of 'Therapy-related acute myelomonocytic leukemia following successful treatment for acute promyelocytic leukemia'. Together they form a unique fingerprint.

Cite this